G lucagon‐like peptide‐1 analogues in monogenic syndromic obesity: Real‐world data from a large cohort of Alström syndrome patients
Authors' conclusion
Data from our centre highlight the non-inferiority of GLP-1 RAs in monogenic syndromic obesity to the available GLP-1 RA-use data in polygenic obesity, therefore, these agents can be considered as a treatment option in patients with ALMS, as well as other forms of monogenic obesity.
Study context
- Population
- UK adults with Alström syndrome (ALMS) with BMI ≥25 kg/m², insulin resistance, suboptimal glycaemic control on antihyperglycaemic medications or NAFLD; mean age 31 ± 11 years, male:female 2:130 completed 6 months
- Participants
- 34 adults
- Exposure
- GLP-1 RA treatment, before vs after 6 months
- GLP-1 RAsn = 30
- Outcome
- Change in body weight and HbA1c
- Follow-up
- 6 months
Methodological detailssingle-centre, 72 UK adult patients with ALMS screened; treatment offered to 34
- Single-centre
- 72 UK adult patients with ALMS screened; treatment offered to 34
Main finding
As reported in the abstract
6 months
Body weight reduction (mean ± SD, 95% CI 3.6-7), equating to 6% weight loss, P < .01
5.4 ± 1.7 kg
HbA1c reduction (95% CI 8.7-15.3), equating to 1.1% absolute reduction, P < .01
12 ± 3.3 mmol/mol
Observational data: associations, not effects.
Further findings
Lipids and alanine aminotransferase · 6 months
- Significant improvements in serum total cholesterol, TG, LDL-C, HDL-C and alanine aminotransferase
- Improvement of metabolic variables comparable with data for polygenic obesity, irrespective of weight loss
Original publication
G lucagon‐like peptide‐1 analogues in monogenic syndromic obesity: Real‐world data from a large cohort of Alström syndrome patients. Diabetes Obes Metab. Published 27 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →